StockMarketWire.com - Citigroup today reaffirms its buy investment rating on Hikma Pharmaceuticals PLC [LON:HIK] and raised its price target to 1675p (from 1475p).

Story provided by StockMarketWire.com

Broker Forecasts data provided by www.sharesmagazine.co.uk